No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki

The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using dat...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Sci
Main Authors: Toriyama, Eo, Hata, Tomoko, Yokota, Ken‐ichi, Chiwata, Masahiko, Kamijo, Rena, Hashimoto, Miki, Taguchi, Masataka, Horai, Makiko, Matsuo, Masatoshi, Matsuo, Emi, Takasaki, Yumi, Kawaguchi, Yasuhisa, Itonaga, Hidehiro, Sato, Shinya, Ando, Koji, Sawayama, Yasushi, Taguchi, Jun, Imaizumi, Yoshitaka, Tsushima, Hideki, Jo, Tatsuro, Yoshida, Shinichiro, Moriuchi, Yukiyoshi, Miyazaki, Yasushi
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2020
主題:
Original Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7734160/
https://ncbi.nlm.nih.gov/pubmed/32939867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14653
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍